ClinicalTrials.gg
CompletedNCT06354556Updated Jun 6, 2024

Effect of Verapamil Tablets on the Pharmacokinetic of HRS-1893 Tablets in Healthy Subjects

A Phase 1 interventional study of HRS-1893 tablet and Verapamil tablet in Obstructive Hypertrophic Cardiomyopathy, sponsored by Shandong Suncadia Medicine Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-06-06.

Sponsored by Shandong Suncadia Medicine Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
14
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 71 studies in Cardiomyopathy, Hypertrophic with a site in China — 30 open to participants now, 43 under way, 2 of them phase 3. Cardiomyopathy, Hypertrophic · China.

Enrollment
35th of 39
14 · median 84
Started
2024
with 9 others
Phase 1
5 of 71
none open now
Registered
39th of 71
by date
Lead sponsor
7 of 71
Shandong Suncadia Medicine Co., Ltd.

Among the 71 studies in Cardiomyopathy, Hypertrophic with a site in China, this one is the 35th largest by enrollment of the 39 interventional ones that give a count, is one of 10 that started in 2024, is one of 5 in phase 1, and was the 39th registered.

Cardiomyopathy, Hypertrophic

363 studies on the registry are indexed under Cardiomyopathy, Hypertrophic; 116 are open to participants now.

Browse Cardiomyopathy, Hypertrophic studies →

Open to participants now

30 of the 71 studies in Cardiomyopathy, Hypertrophic with a site in China are open now. Recruiting first, the newest first:

25 more — sign in →

All 30 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 81 Cardiomyopathy, Hypertrophic studies recruiting now, 55 (68%) set no upper age limit and 8 (10%) stop at 75 or younger; 21 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 71 studies in Cardiomyopathy, Hypertrophic with a site in China, or all of them as a file.
02

Study summary

The purpose of this phase Ⅰ study is to evaluate the effect of oral verapamil tablets on the pharmacokinetics of HRS-1893 in healthy subjects.

03

Conditions studied

  • Obstructive Hypertrophic Cardiomyopathy
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Understand the study procedures and methods, voluntarily participate in the study, comply with study requirements, and sign the written form (ICF).
  2. Male or female aged 18-55(adult healthy volunteers).
  3. (BMI) between 19 and 28 kg/m2.
  4. Normal (ECG).

Exclusion criteria

Exclusion Criteria:

  1. History of persistent tachyarrhythmia and syncope.
  2. A history of stomach or bowel surgery or excision.
  3. Positive results of surface antigen, antibody, syphilis antibody and antibody.
  4. Those who have participated in any clinical trials and have taken study drugs within 3 months before the first administration.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
14 participants (actual)

Study arms

  • Experimental
    Single arm

    Drug: HRS-1893 tablet · Drug: Verapamil tablet

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum observed serum concentration (Cmax) for HRS-1893 after Single dose

    Time frame: from Day 1 to Day 8 after the first dose and from Day 12 to Day 19 after the second dose

  2. Area under the plasma concentration versus time curve from time zero to last measurable timepoint (AUC0-t) for HRS-1893 after single dose

    Time frame: from Day 1 to Day 8 after the first dose and from Day 12 to Day 19 after the second dose

  3. Area under the plasma concentration versus time curve from time zero extrapolated to infinity (AUC0-inf) for HRS-1893 after single dose

    Time frame: from Day 1 to Day 8 after the first dose and from Day 12 to Day 19 after the second dose

Secondary outcomes

  1. Time to maximum observed serum concentration (Tmax) for HRS-1893 after single dose

    Time frame: from Day 1 to Day 8 after the first dose and from Day 12 to Day 19 after the second dose

  2. Elimination half-life (T1/2) for HRS-1893 after single dose

    Time frame: from Day 1 to Day 8 after the first dose and from Day 12 to Day 19 after the second dose

  3. Apparent oral clearance (CL/F) for HRS-1893 after single dose

    Time frame: from Day 1 to Day 8 after the first dose and from Day 12 to Day 19 after the second dose

  4. Apparent volume of distribution (Vz/F) for HRS-1893 after single dose

    Time frame: from Day 1 to Day 8 after the first dose and from Day 12 to Day 19 after the second dose

  5. Accumulated amount of excretion (Ae) for HRS-1893 after single dose

    Time frame: from Day 1 to Day 8 after the first dose and from Day 12 to Day 19 after the second dose

  6. Urinary excretion fraction(fe)for HRS-1893 after single dose

    Time frame: from Day 1 to Day 8 after the first dose and from Day 12 to Day 19 after the second dose

  7. Renal clearance(CLr)for HRS-1893 after single dose

    Time frame: from Day 1 to Day 8 after the first dose and from Day 12 to Day 19 after the second dose

  8. Number of subjects with adverse events and the severity of adverse events

    Time frame: from Day 1 to Day 24 after the first dose

07

Study locations

1 site
  • Beijing Anzhen Hospital
    Beijing, Beijing 100029, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2024 to primary completion in May 2024, 0 months.

Of 12 phase 1 interventional studies under Cardiomyopathy, Hypertrophic, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 12. This study's 0 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 3, 2024
First posted
Apr 9, 2024
StartActual
Apr 26, 2024
Primary completionActual
May 20, 2024
CompletionActual
May 20, 2024
Last update
Jun 6, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 6, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06354556
Responsible party
Sponsor
First posted
Apr 9, 2024
Start date
Apr 26, 2024
Primary completion
May 20, 2024
Completion
May 20, 2024
Last update
Jun 6, 2024

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HRS-1893

Start the discussion